吡格列酮抗动脉粥样硬化作用的研究进展  

The Effect of Pioglitazone on Anti-atherosclerosis

作　　者：李蓉[1] 蔡辉[1] 

机构地区：[1]南方医科大学南京临床医学院南京军区南京总医院,江苏省南京市210002

出　　处：《中国动脉硬化杂志》2011年第9期785-790,共6页Chinese Journal of Arteriosclerosis

基　　金：中国博士后科学基金(20090461491)资助

摘　　要：动脉粥样硬化是一种血管壁慢性炎症发展的病理结果,也是心血管疾病发生发展的病理基础。临床研究发现吡格列酮,一种过氧化体增殖物激活型受体γ激动剂,具有改善糖脂代谢、保护血管内皮功能、减少炎性指标、抑制平滑肌细胞增殖、抗血栓形成、稳定斑块等作用,从而在动脉粥样硬化病理过程中发挥一定保护作用,预防血管病变,降低心血管事件的发生率和死亡率。本文就吡格列酮抗动脉粥样硬化的作用机制作一综述。Atherosclerosis is thought to arise as a result of a chronic inflammatory process within the vessel wall, also the basic pathology of cardiovascular disease. Clinical studies found that pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, can improve glucose and lipid metabolism, protect vascular endothelial function, reduce inflammatory markers, inhibit smooth muscle cell proliferation, anti-thrombosis, stabilize atheromatous plaque and so on, which plays a protective role in the pathological process of atherosclerosis and prevention of vascular disease, reduces the incidence of cardiovascular events and mortality. In this paper, the mechanism of the effect of pioglitazone on anti-atherosclerosis is reviewed.

关 键 词：吡格列酮 动脉粥样硬化 血管细胞 血小板 斑块 再狭窄 

分 类 号：R972.6[医药卫生—药品]